All
Patients With Newly Diagnosed, High-Risk Myeloma See High MRD Negative Rates With Isa-KRd
October 1st 2023Treatment with the combination of Sarclisa, Kyprolis, Revlimid and Isa-KRd generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.